• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

COVID-19 患者糖尿病的影响。

Impact of Diabetes in Patients Diagnosed With COVID-19.

机构信息

Department of Biochemistry and Molecular Biology, Dasman Diabetes Institute, Dasman, Kuwait.

Department of Genetics and Bioinformatics, Dasman Diabetes Institute, Dasman, Kuwait.

出版信息

Front Immunol. 2020 Dec 1;11:576818. doi: 10.3389/fimmu.2020.576818. eCollection 2020.

DOI:10.3389/fimmu.2020.576818
PMID:33335527
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7736089/
Abstract

COVID-19 is a disease caused by the coronavirus SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2), known as a highly contagious disease, currently affecting more than 200 countries worldwide. The main feature of SARS-CoV-2 that distinguishes it from other viruses is the speed of transmission combined with higher risk of mortality from acute respiratory distress syndrome (ARDS). People with diabetes mellitus (DM), severe obesity, cardiovascular disease, and hypertension are more likely to get infected and are at a higher risk of mortality from COVID-19. Among elderly patients who are at higher risk of death from COVID-19, 26.8% have DM. Although the reasons for this increased risk are yet to be determined, several factors may contribute to type-2 DM patients' increased susceptibility to infections. A possible factor that may play a role in increasing the risk in people affected by diabetes and/or obesity is the impaired innate and adaptive immune response, characterized by a state of chronic and low-grade inflammation that can lead to abrupt systemic metabolic alteration. SARS patients previously diagnosed with diabetes or hyperglycemia had higher mortality and morbidity rates when compared with patients who were under metabolic control. Similarly, obese individuals are at higher risk of developing complications from SARS-CoV-2. In this review, we will explore the current and evolving insights pertinent to the metabolic impact of coronavirus infections with special attention to the main pathways and mechanisms that are linked to the pathophysiology and treatment of diabetes.

摘要

新型冠状病毒病(COVID-19)是由冠状病毒 SARS-CoV-2(严重急性呼吸综合征冠状病毒-2)引起的疾病,被称为高度传染性疾病,目前在全球 200 多个国家流行。SARS-CoV-2 的主要特征是传播速度快,且急性呼吸窘迫综合征(ARDS)的死亡率较高。糖尿病(DM)、严重肥胖、心血管疾病和高血压患者更容易感染,且 COVID-19 死亡率较高。在 COVID-19 死亡风险较高的老年患者中,有 26.8%患有 DM。尽管尚未确定这种风险增加的原因,但有几个因素可能导致 2 型糖尿病患者更易感染。可能导致糖尿病和/或肥胖患者感染风险增加的一个因素是先天和适应性免疫反应受损,其特征是慢性和低度炎症状态,可导致全身代谢突然改变。与代谢控制良好的患者相比,先前被诊断患有糖尿病或高血糖的 SARS 患者的死亡率和发病率更高。同样,肥胖个体患 SARS-CoV-2 并发症的风险更高。在本次综述中,我们将探讨与冠状病毒感染的代谢影响相关的当前和不断发展的见解,特别关注与糖尿病病理生理学和治疗相关的主要途径和机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c91a/7736089/61faa6a1e8cd/fimmu-11-576818-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c91a/7736089/118bd08e1377/fimmu-11-576818-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c91a/7736089/61faa6a1e8cd/fimmu-11-576818-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c91a/7736089/118bd08e1377/fimmu-11-576818-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c91a/7736089/61faa6a1e8cd/fimmu-11-576818-g002.jpg

相似文献

1
Impact of Diabetes in Patients Diagnosed With COVID-19.COVID-19 患者糖尿病的影响。
Front Immunol. 2020 Dec 1;11:576818. doi: 10.3389/fimmu.2020.576818. eCollection 2020.
2
Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.评估 BIO101 预防 COVID-19 肺炎患者呼吸恶化的疗效和安全性(COVA 研究):一项随机对照试验研究方案的结构化总结。
Trials. 2021 Jan 11;22(1):42. doi: 10.1186/s13063-020-04998-5.
3
Novel Molecular Evidence Related to COVID-19 in Patients with Diabetes Mellitus.糖尿病患者中与2019冠状病毒病相关的新分子证据
J Clin Med. 2020 Dec 7;9(12):3962. doi: 10.3390/jcm9123962.
4
Factors leading to high morbidity and mortality of COVID-19 in patients with type 2 diabetes.导致 2 型糖尿病患者 COVID-19 发病率和死亡率高的因素。
J Diabetes. 2020 Dec;12(12):895-908. doi: 10.1111/1753-0407.13085. Epub 2020 Sep 2.
5
A review on the immune responses against novel emerging coronavirus (SARS-CoV-2).新型冠状病毒(SARS-CoV-2)免疫反应综述。
Immunol Res. 2021 Jun;69(3):213-224. doi: 10.1007/s12026-021-09198-0. Epub 2021 Apr 29.
6
Diabetes Mellitus and SARS-CoV-2 Infection: Pathophysiologic Mechanisms and Implications in Management.糖尿病与 SARS-CoV-2 感染:病理生理机制及管理意义。
Curr Diabetes Rev. 2021;17(6):e123120189797. doi: 10.2174/1573399817666210101110253.
7
Enhanced endocytosis elevated virulence and severity of SARS-CoV-2 due to hyperglycemia in type 2 diabetic patients.由于2型糖尿病患者的高血糖,增强的内吞作用提高了新冠病毒的毒力和严重程度。
Gene Rep. 2022 Mar;26:101495. doi: 10.1016/j.genrep.2022.101495. Epub 2022 Jan 14.
8
The triumvirate: why hypertension, obesity, and diabetes are risk factors for adverse effects in patients with COVID-19.三者组合:为何高血压、肥胖症和糖尿病是新冠病毒肺炎患者出现不良后果的风险因素。
Acta Diabetol. 2021 Jul;58(7):831-843. doi: 10.1007/s00592-020-01636-z. Epub 2021 Feb 15.
9
Downregulation of microRNA-146a in diabetes, obesity and hypertension may contribute to severe COVID-19.microRNA-146a 在糖尿病、肥胖和高血压中的下调可能导致 COVID-19 重症。
Med Hypotheses. 2021 Jan;146:110448. doi: 10.1016/j.mehy.2020.110448. Epub 2020 Dec 9.
10
The Weight of Obesity in Immunity from Influenza to COVID-19.肥胖对预防流感和 COVID-19 免疫的影响。
Front Cell Infect Microbiol. 2021 Mar 17;11:638852. doi: 10.3389/fcimb.2021.638852. eCollection 2021.

引用本文的文献

1
Factors affecting COVID-19 outcomes in Ireland: findings from a national database of 1,408,249 cases diagnosed between 2020 and 2022.影响爱尔兰新冠疫情结果的因素:来自2020年至2022年期间确诊的1,408,249例病例的国家数据库的研究结果
BMC Public Health. 2025 Aug 21;25(1):2877. doi: 10.1186/s12889-025-24057-5.
2
Metabolic reprogramming in viral infections: the interplay of glucose metabolism and immune responses.病毒感染中的代谢重编程:葡萄糖代谢与免疫反应的相互作用
Front Immunol. 2025 May 16;16:1578202. doi: 10.3389/fimmu.2025.1578202. eCollection 2025.
3
Type 2 diabetes mellitus as a predictor of severe outcomes in COVID-19 - a systematic review and meta-analyses.

本文引用的文献

1
Clinical characteristics of coronavirus disease 2019 (COVID-19) patients in Kuwait.科威特 2019 年冠状病毒病(COVID-19)患者的临床特征。
PLoS One. 2020 Nov 20;15(11):e0242768. doi: 10.1371/journal.pone.0242768. eCollection 2020.
2
Fasting Blood Glucose and COVID-19 Severity: Nonlinearity Matters.空腹血糖与新冠病毒疾病严重程度:非线性关系至关重要。
Diabetes Care. 2020 Dec;43(12):3113-3116. doi: 10.2337/dc20-1941. Epub 2020 Oct 13.
3
Cardiometabolic multimorbidity is associated with a worse Covid-19 prognosis than individual cardiometabolic risk factors: a multicentre retrospective study (CoViDiab II).
2型糖尿病作为COVID-19严重结局的预测因素——一项系统评价和荟萃分析
BMC Infect Dis. 2025 May 19;25(1):719. doi: 10.1186/s12879-025-11089-w.
4
Assessment of serum biomarker changes following the COVID-19 pandemic and vaccination: a cohort study in Sylhet, Bangladesh.评估新冠疫情和疫苗接种后血清生物标志物的变化:孟加拉国锡尔赫特的一项队列研究
Front Public Health. 2025 Feb 21;13:1435930. doi: 10.3389/fpubh.2025.1435930. eCollection 2025.
5
Early Use of Liraglutide for the Treatment of Acute COVID-19 Infection: An Open-Label Single-Center Phase II Safety Study with Biomarker Profiling.利拉鲁肽早期用于治疗急性新型冠状病毒肺炎感染:一项具有生物标志物分析的开放标签单中心II期安全性研究。
Infect Dis Rep. 2025 Jan 10;17(1):5. doi: 10.3390/idr17010005.
6
Clinical characteristics of diabetes patients complicated with COVID-19.COVID-19 合并糖尿病患者的临床特征。
Medicine (Baltimore). 2024 Nov 8;103(45):e39427. doi: 10.1097/MD.0000000000039427.
7
Transient Hyperglycemia in a Patient With Type 2 Diabetes After COVID-19 Messenger RNA Vaccination: A Case Report.2型糖尿病患者在接种新冠病毒信使核糖核酸疫苗后出现短暂性高血糖:一例报告
Cureus. 2024 Jul 6;16(7):e63983. doi: 10.7759/cureus.63983. eCollection 2024 Jul.
8
SARS-CoV-2 Infection Positively Correlates with Hyperglycemia and Inflammatory Markers in COVID-19 Patients: A Clinical Research Study.SARS-CoV-2感染与COVID-19患者的高血糖和炎症标志物呈正相关:一项临床研究
Diseases. 2024 Jul 4;12(7):143. doi: 10.3390/diseases12070143.
9
Hospital Mortality and Morbidity in Diabetic Patients with COVID-19: A Retrospective Analysis from the UAE.阿联酋的一项回顾性分析:COVID-19 糖尿病患者的住院死亡率和发病率。
Int J Environ Res Public Health. 2024 May 29;21(6):697. doi: 10.3390/ijerph21060697.
10
Long-Term Persistence of COVID-Induced Hyperglycemia: A Cohort Study.COVID 相关高血糖的长期持续存在:一项队列研究。
Am J Trop Med Hyg. 2024 Feb 13;110(3):512-517. doi: 10.4269/ajtmh.22-0695. Print 2024 Mar 6.
心血管代谢性多重合并症与比单个心血管代谢风险因素更差的 Covid-19 预后相关:一项多中心回顾性研究(CoViDiab II)。
Cardiovasc Diabetol. 2020 Oct 1;19(1):164. doi: 10.1186/s12933-020-01140-2.
4
Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study.住院期间使用西格列汀治疗与 COVID-19 合并 2 型糖尿病患者的死亡率降低相关:一项多中心、病例对照、回顾性、观察性研究。
Diabetes Care. 2020 Dec;43(12):2999-3006. doi: 10.2337/dc20-1521. Epub 2020 Sep 29.
5
Clinical features of patients with type 2 diabetes with and without Covid-19: A case control study (CoViDiab I).2 型糖尿病合并和不合并新冠病毒(Covid-19)患者的临床特征:一项病例对照研究(CoViDiab I)。
Diabetes Res Clin Pract. 2020 Nov;169:108454. doi: 10.1016/j.diabres.2020.108454. Epub 2020 Sep 21.
6
Use of DPP4 inhibitors in Italy does not correlate with diabetes prevalence among COVID-19 deaths.意大利 DPP4 抑制剂的使用与 COVID-19 死亡病例中的糖尿病患病率无关。
Diabetes Res Clin Pract. 2021 Jan;171:108444. doi: 10.1016/j.diabres.2020.108444. Epub 2020 Sep 16.
7
Factors Associated with Increased Morbidity and Mortality of Obese and Overweight COVID-19 Patients.肥胖和超重COVID-19患者发病率和死亡率增加的相关因素。
Biology (Basel). 2020 Sep 9;9(9):280. doi: 10.3390/biology9090280.
8
Letter to the editor: Comment on GLP-1-based drugs and COVID-19 treatment.致编辑的信:关于基于胰高血糖素样肽-1(GLP-1)的药物与新冠病毒病治疗的评论
Acta Pharm Sin B. 2020 Jul;10(7):1249-1250. doi: 10.1016/j.apsb.2020.05.006. Epub 2020 May 26.
9
Inflammation: A bridge between diabetes and COVID-19, and possible management with sitagliptin.炎症:糖尿病与 COVID-19 之间的桥梁,西他列汀可能对此有一定的治疗作用。
Med Hypotheses. 2020 Oct;143:110111. doi: 10.1016/j.mehy.2020.110111. Epub 2020 Jul 15.
10
The Two Faces of ACE2: The Role of ACE2 Receptor and Its Polymorphisms in Hypertension and COVID-19.血管紧张素转换酶2的两面性:血管紧张素转换酶2受体及其多态性在高血压和2019冠状病毒病中的作用
Mol Ther Methods Clin Dev. 2020 Jun 25;18:321-327. doi: 10.1016/j.omtm.2020.06.017. eCollection 2020 Sep 11.